Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

YTHDF3as a prognostic predictive biomarker of thyroid cancer and its correlation with immune infiltration

Authors: Yihan Zhang, Ying Chen, Ruihua Chen, Hong Zhou, Yi Lin, Bingxin Li, Huaidong Song, Guoqiang Zhou, Mei Dong, Huanbai Xu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Purpose

Thyroid cancer (TC) is one of the most common endocrine malignancies, and its morbidity continues to rise. N6-methyladenosine (m6A) RNA methylation, an epigenetic modification, is an important regulator of gene expression in TC. Therefore, it’s worth finding the characteristics and predictive value of the m6A RNA methylation regulators in thyroid cancer (TC).

Method

RNA-seq data of TC was downloaded from the Cancer Genome Atlas (TCGA) database to screen out the differential expressed regulators. The absolute contraction selection operator (Lasso) Cox regression was used to construct the risk model of m6A methylation regulators. The predictive value of the risk scoring model was evaluated by Kaplan Meier (K-M) analysis and receiver operating characteristic (ROC) curves. The underlying mechanism of m6A methylation regulators in TC was predicted by gene set enrichment analysis (GSEA). Further validation was performed by using immunohistochemistry (IHC) and q-PCR. The correlation between risk-related gene and immune infiltration was evaluated by Tumour Immune Estimation Resource (TIMER).

Results

IGF2BP2, YTHDF1 and YTHDF3 were screened out as strong independent prognostic factors of TC. Then a risk score model was established to further screen the predictors. Finally, according to the results of overall survival (OS) and clinical characteristics of TC, YTHDF3 was screened out as a potential predictor. Meanwhile, IHC and qPCR confirmed that YTHDF3 was expressed differential in TC. The expression of YTHDF3 was positively associated with the infiltration level of CD4+ T cells and macrophages. It was strongly correlated with a variety of immune markers in TC.

Conclusion

We confirmed that YTHDF3 can be used as a potential prognostic biomarker of TC. It not only plays a decisive role in the initiation and development of TC, but also provides a new perspective for understanding the modification of m6A RNA in TC.
Literature
1.
2.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef
3.
Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, ESMO Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856–83.CrossRefPubMed
4.
5.
6.
Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m6A RNA methylation. Nat Rev Genet. 2014;15(5):293–306.CrossRefPubMed
7.
Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m(6)a methylation regulators and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270–4.CrossRefPubMedPubMedCentral
8.
Li Y, Xiao J, Bai J, Tian Y, Qu Y, Chen X, et al. Molecular characterization and clinical relevance of m6A regulators across 33 cancer types. Mol Cancer. 2019;18(1):137.CrossRefPubMedPubMedCentral
9.
Liu X, Li H, Wang J, Chen Z. Personalized Automatic Driving System Based on Reinforcement Learning Technology. In: 2019 4th International Conference on Mechanical, Control and Computer Engineering (ICMCCE), Hohhot, China. 2019. p. 373–3733.
10.
11.
Zhu B, Tse LA, Wang D, Koka H, Zhang T, Abubakar M, et al. Immune gene expression profiling reveals heterogeneity in luminal breast tumors. Breast Cancer Res. 2019;21(1):147.CrossRefPubMedPubMedCentral
12.
13.
Zhang L, Han X, Shi Y. Association of MUC16 Mutation with response to Immune checkpoint inhibitors in solid tumors. JAMA Netw Open. 2020;3(8):e2013201.CrossRefPubMedPubMedCentral
14.
Wang X, Fu X, Zhang J, Xiong C, Zhang S, Lv Y. Identification and validation of m6A RNA methylation regulators regulators with clinical prognostic value in papillary thyroid cancer. Cancer Cell Int. 2020;20(1):203.CrossRefPubMedPubMedCentral
15.
Dedhia PH, Saucke MC, Long KL, Doherty GM, Pitt SC. Physician perspectives of overdiagnosis and overtreatment of low-risk papillary thyroid Cancer in the US. JAMA Netw Open. 2022;5(4):e228722.CrossRefPubMedPubMedCentral
16.
Mulè C, Ciampi R, Ramone T, Prete A, Matrone A, Cappagli V, et al. Higher RET gene expression levels do not represent anAlternative RET activation mechanism in medullary thyroid carcinoma. Biomolecules. 2021;11(10):1542.CrossRefPubMedPubMedCentral
17.
Barletta JA, Nosé V, Sadow PM. Genomics and Epigenomics of Medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocr Pathol. 2021;32(1):35–43.CrossRefPubMedPubMedCentral
18.
19.
20.
Xu N, Chen J, He G, Gao L, Zhang D. Prognostic values of m6A RNA methylation regulators regulators in differentiated thyroid carcinoma. J Cancer. 2020;11(17):5187–97.CrossRefPubMedPubMedCentral
21.
Joerger AC, Fersht AR. The p53 pathway: Origins, inactivation in Cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85:375–404.CrossRefPubMed
22.
Jurczyszak D, Zhang W, Terry SN, Kehrer T, Bermúdez González MC, McGregor E, et al. HIV protease cleaves the antiviral m6A reader protein YTHDF3 in the viral particle. PLoS Pathog. 2020;16(2):e100830536.CrossRef
23.
Wu Y, Jiang D, Zhang H, Yin F, Guo P, Zhang X, et al. N1-Methyladenosine (m1A) regulation Associated with the pathogenesis of abdominal aortic aneurysm through YTHDF3 modulating macrophage polarization. Front Cardiovasc Med. 2022;9:883155.CrossRefPubMedPubMedCentral
24.
Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell. 2014;56(5):617–29.CrossRefPubMed
25.
Ye L, Jiang Y, Zhang M. Crosstalk between glucose metabolism, lactate production and immune response modulation. Cytokine Growth Factor Rev. 2022;68:81–92.CrossRefPubMed
26.
Li W, Xu M, Li Y, Huang Z, Zhou J, Zhao Q, et al. Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer. J Transl Med. 2020;18(1):92.CrossRefPubMedPubMedCentral
27.
Cheng T, Ding S, Liu S, Li Y, Sun L. Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4 + T cell senescence via MiR-199a-5p/Sirt1/p53 axis. Theranostics. 2021;11(2):893–905.CrossRefPubMedPubMedCentral
28.
Song Q, Wang H, Bao J, Pullikuth AK, Li KC. Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer. Sci Rep. 2015;5:12981.CrossRefPubMedPubMedCentral
29.
Metadata
Title
YTHDF3as a prognostic predictive biomarker of thyroid cancer and its correlation with immune infiltration
Authors
Yihan Zhang
Ying Chen
Ruihua Chen
Hong Zhou
Yi Lin
Bingxin Li
Huaidong Song
Guoqiang Zhou
Mei Dong
Huanbai Xu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11361-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis

Study Protocol

Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial

Matters Arising

Kappa statistic considerations in evaluating inter-rater reliability between two raters: which, when and context matters

Research

Notch3 signaling promotes colorectal tumor growth by enhancing immunosuppressive cells infiltration in the microenvironment

Research

99mTc-MAA accumulation within tumor in preoperative lung perfusion SPECT/CT associated with occult lymph node metastasis in patients with clinically N0 non-small cell lung cancer

Research

Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits